📊 ELVN Key Takeaways
Is Enliven Therapeutics, Inc. (ELVN) a Good Investment?
Enliven Therapeutics is a pre-revenue pharmaceutical company with excellent balance sheet strength ($453.4M equity, $132.2M cash, zero debt) but burning $27.8M annually in operating losses with negative free cash flow and no revenue generation. While the company has approximately 7 years of cash runway, the fundamental absence of any revenue stream combined with high pharmaceutical development risk and unclear commercial viability makes this a speculative burn-rate play rather than an operating business.
Enliven Therapeutics has the balance sheet profile of a well-capitalized clinical-stage biotech, with very high liquidity, minimal liabilities, and no meaningful debt. However, the business remains pre-revenue and deeply unprofitable, with sizable operating and free cash flow burn that makes future value creation highly dependent on successful clinical execution rather than current operating fundamentals. The modest improvement in EPS is encouraging, but core profitability and self-funding capacity remain absent.
Enliven Therapeutics, Inc. Key Strengths (ELVN)
- Exceptional balance sheet with $453.4M stockholders' equity and zero long-term debt
- Strong liquidity position with $132.2M cash and 40.32x current ratio providing substantial runway
- Manageable annual burn rate of $19.3M FCF relative to cash position enables multi-year development timeline
- Exceptional liquidity with current and quick ratios of 28.66x
- Strong balance sheet with $459.60M of equity and essentially no leverage
- Net loss and diluted EPS showed year-over-year improvement despite continued R&D investment
ELVN Stock Risks: Enliven Therapeutics, Inc. Investment Risks
- Complete absence of revenue with no clear near-term commercialization path
- Significant operating losses of $27.8M annually with negative operating cash flow
- High pharmaceutical development execution risk; clinical trial failures could accelerate cash depletion and future dilutive financing needs
- No discernible path to profitability without successful drug development and regulatory approval
- No revenue base, making the company fully dependent on pipeline progress and external financing over time
- Large operating loss of $119.66M and negative free cash flow of $70.46M indicate sustained cash burn
- Profitability metrics remain weak, with negative ROE and ROA showing capital is not yet generating returns
Key Metrics to Watch
- Clinical trial milestones and regulatory progress on pipeline candidates
- Quarterly burn rate trend and actual cash consumption vs. projections
- Financing activities and equity dilution; need and terms of future capital raises
- Operating cash flow trend and whether burn accelerates or stabilizes
- Quarterly operating cash burn relative to cash and equivalents
- Any transition from pre-revenue status toward collaboration revenue, milestone revenue, or eventual product sales
Enliven Therapeutics, Inc. (ELVN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 40.32x current ratio provides a solid financial cushion.
ELVN Profit Margin, ROE & Profitability Analysis
ELVN vs Healthcare Sector: How Enliven Therapeutics, Inc. Compares
How Enliven Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Enliven Therapeutics, Inc. Stock Overvalued? ELVN Valuation Analysis 2026
Based on fundamental analysis, Enliven Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Enliven Therapeutics, Inc. Balance Sheet: ELVN Debt, Cash & Liquidity
ELVN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Enliven Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.89 indicates the company is currently unprofitable.
ELVN Revenue Growth, EPS Growth & YoY Performance
Enliven Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
ELVN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Enliven Therapeutics, Inc. (CIK: 0001672619)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ELVN
What is the AI rating for ELVN?
Enliven Therapeutics, Inc. (ELVN) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 74% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ELVN's key strengths?
Claude: Exceptional balance sheet with $453.4M stockholders' equity and zero long-term debt. Strong liquidity position with $132.2M cash and 40.32x current ratio providing substantial runway. ChatGPT: Exceptional liquidity with current and quick ratios of 28.66x. Strong balance sheet with $459.60M of equity and essentially no leverage.
What are the risks of investing in ELVN?
Claude: Complete absence of revenue with no clear near-term commercialization path. Significant operating losses of $27.8M annually with negative operating cash flow. ChatGPT: No revenue base, making the company fully dependent on pipeline progress and external financing over time. Large operating loss of $119.66M and negative free cash flow of $70.46M indicate sustained cash burn.
What is ELVN's revenue and growth?
Enliven Therapeutics, Inc. reported revenue of N/A.
Does ELVN pay dividends?
Enliven Therapeutics, Inc. does not currently pay dividends.
Where can I find ELVN SEC filings?
Official SEC filings for Enliven Therapeutics, Inc. (CIK: 0001672619) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ELVN's EPS?
Enliven Therapeutics, Inc. has a diluted EPS of $-0.38.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ELVN's fundamental grade?
Based on our AI fundamental analysis in June 2026, Enliven Therapeutics, Inc. has a C grade with 74% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ELVN stock overvalued or undervalued?
Valuation metrics for ELVN: ROE of -5.2% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ELVN's AI grade for 2026?
Our dual AI analysis gives Enliven Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ELVN's free cash flow?
Enliven Therapeutics, Inc.'s operating cash flow is $-19.3M, with capital expenditures of $0.0.
How does ELVN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -5.2% (avg: 15%), current ratio 40.32 (avg: 2).